ReviewAmerican journal of cancer research2015

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Mariana Segovia-Mendoza et al.PubMed ↗Full text ↗

No numbers read from the abstract.